SCHEMBL6920764

SCHEMBL6920764

CN1CCn2c(nc3cc([Si](C)(C)C)ccc3c2=O)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39
BCHE P06276 1/20 0.39
CFTR P13569 1/20 0.39
ALOX15 P16050 1/20 0.39
ACHE P22303 1/20 0.39
HKDC1 Q2TB90 1/20 0.39
GOPC Q9HD26 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921733 0.83 HRH4 (0.46) LMNACYP2C19ALDH1A1KDM4EL3MBTL1
SCHEMBL12059176 0.83 CYP2C19 (0.46) LMNACYP2C19ALDH1A1KDM4EL3MBTL1
SCHEMBL6921507 0.80 CYP2C19 (0.43) LMNACYP2C19ALDH1A1KDM4EL3MBTL1
SCHEMBL9994973 0.79 CYP2C19 (0.41) LMNACYP2C19ALDH1A1KDM4EL3MBTL1
SCHEMBL12059374 0.79 MEN1 (0.63) LMNACYP2C19ALDH1A1KDM4EL3MBTL1
SCHEMBL6923306 0.79 RAB9A (0.43) LMNACYP2C19ALDH1A1L3MBTL1CYP1A2
SCHEMBL6922315 0.78 ALDH1A1 (0.38) LMNACYP2C19ALDH1A1KDM4EL3MBTL1
SCHEMBL6922611 0.76 ALDH1A1 (0.44) LMNACYP2C19ALDH1A1KDM4EL3MBTL1
SCHEMBL9994512 0.76 RAB9A (0.41) LMNACYP2C19ALDH1A1L3MBTL1CYP1A2
SCHEMBL6922377 0.76 LMNA (0.41) LMNACYP2C19SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 LMNA 4613/4885CYP2C19 4711/4885ALDH1A1 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.